Ibrutinib Regimens Outperform Chemoimmunotherapy in Newly Diagnosed CLL

From December 1 to December 4, more than 25,000 attendees from around the world gathered in San Diego, California, to attend the 60th American Society for Hematology (ASH) Annual Meeting, where the latest developments and new findings in the hematology field were presented. Over the next several weeks, prIME Lines will highlight some of the […]

Read More

FDA Approved 11 New Cancer Treatments in October and November

Three New Therapies for Acute Myeloid Leukemia. The United States Food and Drug Administration (FDA) granted approval for three new agents for acute myeloid leukemia (AML) in November. Gilteritinib (Xospata®, Astellas), a FLT3-targeting tyrosine kinase inhibitor (TKI), was approved for use in adults with relapsed or refractory AML who have an FLT3 mutation, as detected […]

Read More

Regorafenib Delays Progression in Advanced Osteosarcoma

Treatment options for patients with metastatic osteosarcoma who progress on first-line chemotherapy are limited, and prognosis for these patients is extremely poor. The activity of second-line chemotherapy in osteosarcoma is marginal, and treatment with checkpoint inhibitors, unfortunately, also appears ineffective. More promising results were reported with targeted therapy, in particular with agents targeting angiogenesis and […]

Read More